Titre :

Comparable outcomes of haploidentical transplant with tbf conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia

Auteur(s) :

Bazarbachi, Ali [Auteur]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Blaise, Didier [Auteur]
Forcade, Edouard [Auteur]
Socie, Gerard [Auteur]
Berceanu, Ana [Auteur]
Angelucci, Emanuele [Auteur]
Bulabois, Claude-Éric [Auteur]
Université Grenoble Alpes [2016-2019] [UGA [2016-2019]]
Krger, Nicolaus [Auteur]
Rambaldi, Alessandro [Auteur]
Ceballos, Patrice [Auteur]
Mielke, Stephan [Auteur]
El Cheikh, Jean [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Savani, Bipin N. [Auteur]
Spyridonidis, Alexandros [Auteur]
Nagler, Arnon [Auteur]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Numéro :

56

Pagination :

622–634

Date de publication :

2021-03

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant ...
Lire la suite >We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion. For intermediate cytogenetic risk AML transplanted in first complete remission (CR1), multivariate analysis revealed that haplo-TBF significantly increased nonrelapse mortality (NRM) (HR 2.1; p = 0.0006) but did not affect relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), or graft-versus-host disease-free, relapse-free survival (GRFS). For high cytogenetic risk AML transplanted in CR1, haplo-TBF significantly increased NRM (HR = 2.7; p = 0.02), decreased RI (HR = 0.45; p = 0.03) but had no influence on LFS, OS, or GRFS. For AML transplanted in CR2, haplo-TBF significantly increased NRM (HR = 2.36; p = 0.008), decreased RI (HR = 0.38; p = 0.005), but had no influence on LFS, OS, or GRFS. Finally, for AML patients transplanted with active disease, haplo-TBF had no influence on transplant outcomes. In conclusion, compared to MUD-FB, haplo-TBF increased NRM, reduced RI in high-risk AML in CR, resulting in similar LFS, OS, and GRFS. These results comparing two different approaches support the use of a haploidentical family donor for high-risk AML patients lacking a matched sibling donor.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:02Z
2024-01-09T12:45:50Z